Improving T cell therapies for cancer treatment
Decoding and reprogramming T cells through synthetic biology for cancer immunotherapy
This study is exploring new ways to make T cell therapies for cancer even better by using special techniques to change their DNA, which could help them work more effectively against tumors that they’ve been exposed to for a long time.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | J. David Gladstone Institutes NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-10995277 on NIH RePORTER |
What this research studies
This research focuses on enhancing T cell-based therapies for cancer by using synthetic biology techniques. The team aims to design new T cell therapies that are more effective and can overcome dysfunction caused by chronic exposure to tumor antigens. They will utilize advanced CRISPR technology to insert new synthetic DNA sequences into T cells, which may improve their ability to fight cancer. By screening various genes and gene programs, the researchers hope to discover innovative ways to boost the therapeutic functions of T cells.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with cancers that have not responded to existing T cell therapies.
Not a fit: Patients with early-stage cancers or those who have not yet undergone T cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer treatments that improve patient outcomes.
How similar studies have performed: Previous research has shown promise in enhancing T cell therapies using similar synthetic biology approaches, indicating potential for success in this area.
Where this research is happening
San Francisco, United States
- J. David Gladstone Institutes — San Francisco, United States (Active)
Researchers
- Principal investigator: Marson, Alexander — J. David Gladstone Institutes
- Study coordinator: Marson, Alexander
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.